Genetic Testing Disclosure in Clinical Trials

This technical report discusses the complexities surrounding the disclosure of genetic screening results to patients involved in clinical trials, particularly in the context of rare genetic diseases. It outlines the responsibilities of sponsors regarding additional testing and the ambiguous guidelines that exist in this area. The report emphasizes the importance of understanding various factors that influence the decision to share or withhold genetic information, including regulatory frameworks in different countries, ethical considerations, and the potential impact on patient care. It also details the best practices for implementing genetic testing in clinical development strategies, highlighting the need for careful planning and coordination among stakeholders. The report addresses the rationale for non-disclosure, ethical dilemmas, and the significance of providing accurate information to patients while managing public perception. Furthermore, it stresses the importance of laboratory selection and the implications of inaccurate reporting on trial outcomes and patient experiences.